extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

agents/vida/frontier.md

@@ -0,0 +1,131 @@
+# Vida's Knowledge Frontier
+
+**Last updated:** 2026-03-16 (first self-audit)
+
+These are the gaps in Vida's health domain knowledge base, ranked by impact on active beliefs. Each gap is a contribution invitation — if you have evidence, experience, or analysis that addresses one of these, the collective wants it.
+
+---
+
+## 1. Behavioral Health Infrastructure Mechanisms
+
+**Why it matters:** Belief 2 — "80-90% of health outcomes are non-clinical" — depends on non-clinical interventions actually working at scale. The health KB has strong evidence that medical care explains only 10-20% of outcomes, but almost nothing about WHAT works to change the other 80-90%.
+
+**What's missing:**
+- Community health worker program outcomes (ROI, scalability, retention)
+- Social prescribing mechanisms and evidence (UK Link Workers, international models)
+- Digital therapeutics for behavior change (post-PDT market failure — what survived?)
+- Behavioral economics of health (commitment devices, default effects, incentive design)
+- Food-as-medicine programs (Geisinger Fresh Food Farmacy, produce prescription ROI)
+
+**Adjacent claims:**
+- medical care explains only 10-20 percent of health outcomes...
+- SDOH interventions show strong ROI but adoption stalls...
+- social isolation costs Medicare 7 billion annually...
+- modernization dismantles family and community structures...
+
+**Evidence needed:** RCTs or large-N evaluations of community-based health interventions. Cost-effectiveness analyses. Implementation science on what makes SDOH programs scale vs stall.
+
+---
+
+## 2. International and Comparative Health Systems
+
+**Why it matters:** Every structural claim in the health KB is US-only. This limits generalizability and misses natural experiments that could strengthen or challenge the attractor state thesis.
+
+**What's missing:**
+- Singapore's 3M system (Medisave/Medishield/Medifund) — consumer-directed with catastrophic coverage
+- Costa Rica's EBAIS primary care model — universal coverage at 8% of US per-capita spend
+- Japan's Long-Term Care Insurance — aging population, community-based care at scale
+- NHS England — what underfunding + wait times reveal about single-payer failure modes
+- Kerala's community health model — high outcomes at low GDP
+
+**Adjacent claims:**
+- the healthcare attractor state is a prevention-first system...
+- healthcare is a complex adaptive system requiring simple enabling rules...
+- four competing payer-provider models are converging toward value-based care...
+
+**Evidence needed:** Comparative health system analyses. WHO/Commonwealth Fund cross-national data. Case studies of systems that achieved prevention-first economics.
+
+---
+
+## 3. GLP-1 Second-Order Economics
+
+**Why it matters:** GLP-1s are the largest therapeutic category launch in pharmaceutical history. One claim captures market size, but the downstream economic and behavioral effects are uncharted.
+
+**What's missing:**
+- Long-term adherence data at population scale (current trials are 2-4 years)
+- Insurance coverage dynamics (employer vs Medicare vs cash-pay trajectories)
+- Impact on adjacent markets (bariatric surgery demand, metabolic syndrome treatment)
+- Manufacturing bottleneck economics (Novo/Lilly duopoly, biosimilar timeline)
+- Behavioral rebound after discontinuation (weight regain rates, metabolic reset)
+
+**Adjacent claims:**
+- GLP-1 receptor agonists are the largest therapeutic category launch...
+- the healthcare cost curve bends up through 2035...
+- consumer willingness to pay out of pocket for AI-enhanced care...
+
+**Evidence needed:** Real-world adherence studies (not trial populations). Actuarial analyses of GLP-1 impact on total cost of care. Manufacturing capacity forecasts.
+
+---
+
+## 4. Clinical AI Real-World Safety Data
+
+**Why it matters:** Belief 5 — clinical AI safety risks — is grounded in theoretical mechanisms (human-in-the-loop degradation, benchmark vs clinical performance gap) but thin on deployment data.
+
+**What's missing:**
+- Deployment accuracy vs benchmark accuracy (how much does performance drop in real clinical settings?)
+- Alert fatigue rates in AI-augmented clinical workflows
+- Liability incidents and near-misses from clinical AI deployments
+- Autonomous diagnosis failure modes (systematic biases, demographic performance gaps)
+- Clinician de-skilling longitudinal data (is the human-in-the-loop degradation measurable over years?)
+
+**Adjacent claims:**
+- human-in-the-loop clinical AI degrades to worse-than-AI-alone...
+- medical LLM benchmark performance does not translate to clinical impact...
+- AI diagnostic triage achieves 97 percent sensitivity...
+- healthcare AI regulation needs blank-sheet redesign...
+
+**Evidence needed:** Post-deployment surveillance studies. FDA adverse event reports for AI/ML medical devices. Longitudinal studies of clinician performance with and without AI assistance.
+
+---
+
+## 5. Space Health (Cross-Domain Bridge to Astra)
+
+**Why it matters:** Space medicine is a natural cross-domain connection that's completely unbuilt. Radiation biology, bone density loss, psychological isolation, and closed-loop life support all have terrestrial health parallels.
+
+**What's missing:**
+- Radiation biology and cancer risk in long-duration spaceflight
+- Bone density and muscle atrophy countermeasures (pharmaceutical + exercise protocols)
+- Psychological health in isolation and confinement (Antarctic, submarine, ISS data)
+- Closed-loop life support as a model for self-sustaining health systems
+- Telemedicine in extreme environments (latency-tolerant protocols, autonomous diagnosis)
+
+**Adjacent claims:**
+- social isolation costs Medicare 7 billion annually...
+- the physician role shifts from information processor to relationship manager...
+- continuous health monitoring is converging on a multi-layer sensor stack...
+
+**Evidence needed:** NASA Human Research Program publications. ESA isolation studies (SIRIUS, Mars-500). Telemedicine deployment data from remote/extreme environments.
+
+---
+
+## 6. Health Narratives and Meaning (Cross-Domain Bridge to Clay)
+
+**Why it matters:** The health KB asserts that 80-90% of outcomes are non-clinical, and that modernization erodes meaning-making structures. But the connection between narrative, identity, meaning, and health outcomes is uncharted.
+
+**What's missing:**
+- Placebo and nocebo mechanisms — what the placebo effect reveals about narrative-driven physiology
+- Narrative identity in chronic illness — how patients' stories about their condition affect outcomes
+- Meaning-making as health intervention — Viktor Frankl to modern logotherapy evidence
+- Community and ritual as health infrastructure — religious attendance, group membership, and mortality
+- Deaths of despair as narrative failure — the connection between meaning-loss and self-destructive behavior
+
+**Adjacent claims:**
+- Americas declining life expectancy is driven by deaths of despair...
+- modernization dismantles family and community structures...
+- social isolation costs Medicare 7 billion annually...
+
+**Evidence needed:** Psychoneuroimmunology research. Longitudinal studies on meaning/purpose and health outcomes. Comparative data on health outcomes in high-social-cohesion vs low-social-cohesion communities.
+
+---
+
+*Generated from Vida's first self-audit (2026-03-16). These gaps are ranked by impact on active beliefs — Gap 1 affects the foundational claim that non-clinical factors drive health outcomes, which underpins the entire prevention-first thesis.*

agents/vida/self-audit-2026-03-16.md

@@ -0,0 +1,138 @@
+# Self-Audit Report: Vida
+**Date:** 2026-03-16
+**Domain:** health
+**Claims audited:** 44
+**Overall status:** WARNING
+
+---
+
+## Structural Findings
+
+### Schema Compliance: PASS
+- 44/44 files have all required frontmatter (type, domain, description, confidence, source, created)
+- 44/44 descriptions add meaningful context beyond the title
+- 3 files use non-standard extended fields (last_evaluated, depends_on, challenged_by, secondary_domains, tradition) — these are useful extensions but should be documented in schemas/claim.md if adopted collectively
+
+### Orphan Ratio: CRITICAL — 74% (threshold: 15%)
+- 35 of 47 health claims have zero incoming wiki links from other claims or agent files
+- All 12 "connected" claims receive links only from inbox/archive source files, not from the knowledge graph
+- **This means the health domain is structurally isolated.** Claims link out to each other internally, but no other domain or agent file links INTO health claims.
+
+**Classification of orphans:**
+- 15 AI/technology claims — should connect to ai-alignment domain
+- 8 business/market claims — should connect to internet-finance, teleological-economics
+- 8 policy/structural claims — should connect to mechanisms, living-capital
+- 4 foundational claims — should connect to critical-systems, cultural-dynamics
+
+**Root cause:** Extraction-heavy, integration-light. Claims were batch-extracted (22 on Feb 17 alone) without a corresponding integration pass to embed them in the cross-domain graph.
+
+### Link Health: PASS
+- No broken wiki links detected in claim bodies
+- All `wiki links` resolve to existing files
+
+### Staleness: PASS (with caveat)
+- All claims created within the last 30 days (domain is new)
+- However, 22/44 claims cite evidence from a single source batch (Bessemer State of Health AI 2026). Source diversity is healthy at the domain level but thin at the claim level.
+
+### Duplicate Detection: PASS
+- No semantic duplicates found
+- Two near-pairs worth monitoring:
+  - "AI diagnostic triage achieves 97% sensitivity..." and "medical LLM benchmark performance does not translate to clinical impact..." — not duplicates but their tension should be explicit
+  - "PACE demonstrates integrated care averts institutionalization..." and "PACE restructures costs from acute to chronic..." — complementary, not duplicates
+
+---
+
+## Epistemic Findings
+
+### Unacknowledged Contradictions: 3 (HIGH PRIORITY)
+
+**1. Prevention Economics Paradox**
+- Claim: "the healthcare attractor state...profits from health rather than sickness" (likely)
+- Claim: "PACE restructures costs from acute to chronic spending WITHOUT REDUCING TOTAL EXPENDITURE" (likely)
+- PACE is the closest real-world approximation of the attractor state (100% capitation, fully integrated, community-based). It shows quality/outcome improvement but cost-neutral economics. The attractor state thesis assumes prevention is profitable. PACE says it isn't — the value is clinical and social, not financial.
+- **The attractor claim's body addresses this briefly but the tension is buried, not explicit in either claim's frontmatter.**
+
+**2. Jevons Paradox vs AI-Enabled Prevention**
+- Claim: "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand" (likely)
+- Claim: "the healthcare attractor state" relies on "AI-augmented care delivery" for prevention
+- The Jevons claim asserts ALL healthcare AI optimizes sick care. The attractor state assumes AI can optimize prevention. Neither acknowledges the other.
+
+**3. Cost Curve vs Attractor State Timeline**
+- Claim: "the healthcare cost curve bends UP through 2035" (likely)
+- Claim: "GLP-1s...net cost impact inflationary through 2035" (likely)
+- Claim: attractor state assumes prevention profitability
+- If costs are structurally inflationary through 2035, the prevention-first attractor can't achieve financial sustainability during the transition period. This timeline constraint isn't acknowledged.
+
+### Confidence Miscalibrations: 3
+
+**Overconfident (should downgrade):**
+1. "Big Food companies engineer addictive products by hacking evolutionary reward pathways" — rated `proven`, should be `likely`. The business practices are evidenced but "intentional hacking" of reward pathways is interpretation, not empirically proven via RCT.
+2. "AI scribes reached 92% provider adoption" — rated `proven`, should be `likely`. The 92% figure is "deploying, implementing, or piloting" (Bessemer), not proven adoption. The causal "because" clause is inferred.
+3. "CMS 2027 chart review exclusion targets vertical integration profit arbitrage" — rated `proven`, should be `likely`. CMS intent is inferred from policy mechanics, not explicitly documented.
+
+**Underconfident (could upgrade):**
+1. "consumer willingness to pay out of pocket for AI-enhanced care" — rated `likely`, could be `proven`. RadNet study (N=747,604) showing 36% choosing $40 AI premium is large-scale empirical market behavior data.
+
+### Belief Grounding: WARNING
+- Belief 1 ("healthspan is the binding constraint") — well-grounded in 7+ claims
+- Belief 2 ("80-90% of health outcomes are non-clinical") — grounded in `medical care explains 10-20%` (proven) but THIN on what actually works to change behavior. Only 1 claim touches SDOH interventions, 1 on social isolation. No claims on community health workers, social prescribing mechanisms, or behavioral economics of health.
+- Belief 3 ("structural misalignment") — well-grounded in CMS, payvidor, VBC claims
+- Belief 4 ("atoms-to-bits") — grounded in wearables + Function Health claims
+- Belief 5 ("clinical AI + safety risks") — grounded in human-in-the-loop degradation, benchmark vs clinical impact. But thin on real-world deployment safety data.
+
+### Scope Issues: 3
+
+1. "AI-first screening viable for ALL imaging and pathology" — evidence covers 14 CT conditions and radiology, not all imaging/pathology modalities. Universal is unwarranted.
+2. "the physician role SHIFTS from information processor to relationship manager" — stated as completed fact; evidence shows directional trend, not completed transformation.
+3. "the healthcare attractor state...PROFITS from health" — financial profitability language is stronger than PACE evidence supports. "Incentivizes health" would be more accurate.
+
+---
+
+## Knowledge Gaps (ranked by impact on beliefs)
+
+1. **Behavioral health infrastructure mechanisms** — Belief 2 depends on non-clinical interventions working at scale. Almost no claims about WHAT works: community health worker programs, social prescribing, digital therapeutics for behavior change. This is the single biggest gap.
+
+2. **International/comparative health systems** — Zero non-US claims. Singapore 3M, Costa Rica EBAIS, Japan LTCI, NHS England are all in the archive but unprocessed. Limits the generalizability of every structural claim.
+
+3. **GLP-1 second-order economics** — One claim on market size. Nothing on: adherence at scale, insurance coverage dynamics, impact on bariatric surgery demand, manufacturing bottlenecks, Novo/Lilly duopoly dynamics.
+
+4. **Clinical AI real-world safety data** — Belief 5 claims safety risks but evidence is thin. Need: deployment accuracy vs benchmark, alert fatigue rates, liability incidents, autonomous diagnosis failure modes.
+
+5. **Space health** — Zero claims. Cross-domain bridge to Astra is completely unbuilt. Radiation biology, bone density, psychological isolation — all relevant to both space medicine and terrestrial health.
+
+6. **Health narratives and meaning** — Cross-domain bridge to Clay is unbuilt. Placebo mechanisms, narrative identity in chronic illness, meaning-making as health intervention.
+
+---
+
+## Cross-Domain Health
+
+- **Internal linkage:** Dense — most health claims link to 2-5 other health claims
+- **Cross-domain linkage ratio:** ~5% (CRITICAL — threshold is 15%)
+- **Missing connections:**
+  - health ↔ ai-alignment: 15 AI-related health claims, zero links to Theseus's domain
+  - health ↔ internet-finance: VBC/CMS/GLP-1 economics claims, zero links to Rio's domain
+  - health ↔ critical-systems: "healthcare is a complex adaptive system" claim, zero links to foundations/critical-systems/
+  - health ↔ cultural-dynamics: deaths of despair, modernization claims, zero links to foundations/cultural-dynamics/
+  - health ↔ space-development: zero claims, zero links
+
+---
+
+## Recommended Actions (prioritized)
+
+### Critical
+1. **Resolve prevention economics contradiction** — Add `challenged_by` to attractor state claim pointing to PACE cost evidence. Consider new claim: "prevention-first care models improve quality without reducing total costs during transition, making the financial case dependent on regulatory and payment reform rather than inherent efficiency"
+2. **Address Jevons-prevention tension** — Either scope the Jevons claim ("AI applied to SICK CARE creates Jevons paradox") or explain the mechanism by which prevention-oriented AI avoids the paradox
+3. **Integration pass** — Batch PR adding incoming wiki links from core/, foundations/, and other domains/ to the 35 orphan claims. This is the highest-impact structural fix.
+
+### High
+4. **Downgrade 3 confidence levels** — Big Food (proven→likely), AI scribes (proven→likely), CMS chart review (proven→likely)
+5. **Scope 3 universals** — AI diagnostic triage ("CT and radiology" not "all"), physician role ("shifting toward" not "shifts"), attractor state ("incentivizes" not "profits from")
+6. **Upgrade 1 confidence level** — Consumer willingness to pay (likely→proven)
+
+### Medium
+7. **Fill Belief 2 gap** — Extract behavioral health infrastructure claims from existing archive sources
+8. **Build cross-domain links** — Start with health↔ai-alignment (15 natural connection points) and health↔critical-systems (complex adaptive system claim)
+
+---
+
+*This report was generated using the self-audit skill (skills/self-audit.md). First audit of the health domain.*

domains/entertainment/GenAI adoption in entertainment will be gated by consumer acceptance not technology capability.md

@@ -29,10 +29,16 @@ The emergence of 'human-made' as a premium label in 2026 provides concrete evide
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-07-01-emarketer-consumers-rejecting-ai-creator-content]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2025-07-01-emarketer-consumers-rejecting-ai-creator-content | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 The 60%→26% collapse in consumer enthusiasm for AI-generated creator content between 2023-2025 (Billion Dollar Boy survey, July 2025, 4,000 consumers) provides the clearest longitudinal evidence that consumer acceptance is the binding constraint. This decline occurred during a period of significant AI quality improvement, definitively proving that capability advancement does not automatically translate to consumer acceptance. The emergence of 'AI slop' as mainstream consumer terminology indicates organized rejection is forming. Additionally, 32% of consumers now say AI negatively disrupts the creator economy (up from 18% in 2023), and 31% say AI in ads makes them less likely to pick a brand (CivicScience, July 2025).
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-koinsights-authenticity-premium-ai-rejection]] | Added: 2026-03-16*
+
+The binding constraint is specifically a moral disgust response in emotionally meaningful contexts, not just general acceptance issues. Journal of Business Research found that AI authorship triggers moral disgust even when content is identical to human-written versions. This suggests the gate is values-based rejection, not quality assessment.
+
 ---
 
 Relevant Notes:

domains/entertainment/consumer-acceptance-of-ai-creative-content-declining-despite-quality-improvements-because-authenticity-signal-becomes-more-valuable.md

@@ -29,6 +29,12 @@ The timing is significant: this acceptance collapse occurred while major brands
 ## Challenges
 The data is specific to creator content and may not generalize to all entertainment formats. Interactive AI experiences or AI-assisted (rather than AI-generated) content may face different acceptance dynamics. The surveys capture stated preferences, which may differ from revealed preferences in actual consumption behavior. The source material does not provide independent verification of the 60%→26% figure beyond eMarketer's citation of Billion Dollar Boy.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-koinsights-authenticity-premium-ai-rejection]] | Added: 2026-03-16*
+
+Deloitte 2024 Connected Consumer Survey found nearly 70% of respondents are concerned AI-generated content will be used to deceive them. Approximately half of consumers now believe they can recognize AI-written content, with many disengaging when brands appear to rely heavily on it in emotionally meaningful contexts.
+
 ---
 
 Relevant Notes:

domains/entertainment/consumer-ai-acceptance-diverges-by-use-case-with-creative-work-facing-4x-higher-rejection-than-functional-applications.md

@@ -27,6 +27,12 @@ The creative-versus-functional distinction also explains why the 60%→26% colla
 ## Implications
 This use-case divergence suggests that entertainment companies should pursue AI adoption asymmetrically: aggressive investment in backend production efficiency and infrastructure, but cautious deployment in consumer-facing creative applications where the "AI-made" signal itself may damage value. The strategy is to use AI where consumers don't see it, not where they do.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-koinsights-authenticity-premium-ai-rejection]] | Added: 2026-03-16*
+
+The divergence is strongest in contexts with high emotional stakes, cultural significance, visible human craft, and trust requirements. The McDonald's Christmas ad case demonstrates that even high-production-value AI content (10 people, 5 weeks) faces rejection in emotionally meaningful contexts.
+
 ---
 
 Relevant Notes:

domains/entertainment/content-serving-commercial-functions-can-simultaneously-serve-meaning-functions-when-revenue-model-rewards-relationship-depth.md

@@ -29,6 +29,12 @@ This challenges the assumption that commercial optimization necessarily degrades
 - Academic framing of tour as "cultural touchstone" where "audiences see themselves reflected in Swift's evolution"
 - 3-hour concert functioning as "the soundtrack of millions of lives" (simultaneous coordination at scale)
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-01-01-sage-algorithmic-content-creation-systematic-review]] | Added: 2026-03-16*
+
+LinkedIn's algorithm redesign to 'emphasize authentic professional storytelling over promotional content' and actively demote 'engagement baiting tactics' demonstrates that platform-level intervention can realign commercial incentives with meaning functions. This confirms that revenue model architecture determines whether commercial and meaning functions align or conflict.
+
 ---
 
 Relevant Notes:

domains/entertainment/human-made-is-becoming-a-premium-label-analogous-to-organic-as-AI-generated-content-becomes-dominant.md

@@ -40,10 +40,16 @@ This represents a scarcity inversion: as AI-generated content becomes abundant a
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-07-01-emarketer-consumers-rejecting-ai-creator-content]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2025-07-01-emarketer-consumers-rejecting-ai-creator-content | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 The 60%→26% enthusiasm collapse for AI-generated creator content (2023-2025) while AI quality improved demonstrates that the 'human-made' signal is becoming more valuable precisely as AI capability increases. The Goldman Sachs finding that 54% of Gen Z reject AI in creative work (versus 13% in shopping) shows consumers are willing to pay the premium specifically in domains where authenticity and human creativity are core to the value proposition. The mainstream adoption of 'AI slop' as consumer terminology indicates the market is actively creating language to distinguish and devalue AI-generated content, which is the precursor to premium human-made positioning.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-koinsights-authenticity-premium-ai-rejection]] | Added: 2026-03-16*
+
+The 'authenticity premium' is now measurable across multiple studies. Nuremberg Institute (2025) found that simply labeling an ad as AI-generated lowers ad attitudes and willingness to purchase, creating a quantifiable trust penalty for AI authorship.
+
 ---
 
 Relevant Notes:

domains/entertainment/media disruption follows two sequential phases as distribution moats fall first and creation moats fall second.md

@@ -23,6 +23,12 @@ The two-moat framework has cross-domain implications. In healthcare, distributio
 
 Swift's strategy confirms the two-phase disruption model. Phase 1 (distribution): Direct AMC theater deal and streaming control bypass traditional film and music distributors. Phase 2 (creation): Re-recordings demonstrate creator control over production and IP ownership, not just distribution access. The $4.1B tour revenue (7x recorded music revenue) shows distribution disruption is further advanced than creation disruption—live performance and direct distribution capture more value than recorded music creation. This supports the claim that distribution moats fall first (Swift captured studio margins through direct exhibition), while creation moats remain partially intact (she still relies on compositions written during label era).
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-mckinsey-ai-film-tv-production-future]] | Added: 2026-03-16*
+
+McKinsey's finding that distributors capture most value from AI production efficiency adds a third phase insight: even as creation costs fall (phase 2), value doesn't automatically flow to creators—it flows to whoever controls distribution. This suggests the two-phase model needs refinement: phase 2 (creation moat collapse) benefits creators only if phase 1 (distribution alternatives) has already occurred.
+
 ---
 
 Relevant Notes:

domains/entertainment/non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain.md

@@ -23,6 +23,12 @@ If non-ATL costs fall to thousands or millions rather than hundreds of millions,
 
 A concrete early signal: a 9-person team reportedly produced an animated film for ~$700K. The trajectory is from $200M to potentially $1M or less for competitive content, with the timeline gated by consumer acceptance rather than technology capability.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-mckinsey-ai-film-tv-production-future]] | Added: 2026-03-16*
+
+McKinsey projects $10B of US original content spend (approximately 20% of total) will be addressable by AI by 2030, with single-digit productivity improvements already visible in some use cases. However, AI-generated output is not yet at quality level to drive meaningful disruption in premium production.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -19,19 +19,19 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 
 ### Additional Evidence (extend)
-*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
 
 ### Additional Evidence (extend)
-*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
 
 ### Additional Evidence (extend)
-*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15*
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
@@ -39,7 +39,7 @@ MA plans' near-universal prior authorization creates administrative friction tha
 ### Additional Evidence (challenge)
 *Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
 
-Aon's 192K patient study shows medical costs rise 23% in year 1 but only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests GLP-1s are cost-saving for long-term risk-bearers, not inflationary—the 'inflationary through 2035' claim may only apply to short-term payers like employers with high turnover.
+Aon's real-world data challenges the 'inflationary through 2035' thesis by showing medical cost growth for GLP-1 users drops to 2% after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. The net impact depends entirely on payer time horizon: short-term payers see inflation, long-term risk-bearers see deflation. The 'inflationary' conclusion may be an artifact of analyzing systems dominated by short-term payment models rather than an inherent property of the drugs.
 
 ---
 

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -31,10 +31,16 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
 
+### Additional Evidence (extend)
+*Source: [[2025-12-23-jama-cardiology-select-hospitalization-analysis]] | Added: 2026-03-16*
+
+SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
+
+
 ### Additional Evidence (extend)
 *Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
 
-Aon study adds cancer risk reduction to the multi-organ protection profile: 50% lower ovarian cancer and 14% lower breast cancer in female users, plus lower rates of osteoporosis, rheumatoid arthritis, and alcohol/drug abuse hospitalizations. The sex-differential in MACE (47% female vs 26% male) suggests organ-specific protection may be stronger in women.
+Aon data adds cancer risk reduction to the multi-organ protection profile: female users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence, plus lower rates of osteoporosis and rheumatoid arthritis. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests protective mechanisms may be stronger or more diverse in women. This expands the value proposition beyond the kidney and cardiovascular endpoints already documented.
 
 ---
 

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -51,7 +51,7 @@ No data yet on whether payment model affects persistence—does being in an MA p
 ### Additional Evidence (extend)
 *Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
 
-Aon data shows benefits scale dramatically with adherence: 80%+ adherent users show 9 percentage point lower cost growth (vs 6 points for all users) in diabetes and 7 points lower (vs 3 points) in weight loss. This confirms that the adherence crisis undermines the economic case, but also shows the potential value if adherence can be improved.
+Aon data shows adherence is the binding variable for GLP-1 cost-effectiveness: the 80%+ adherent cohort shows dramatically stronger effects across all outcomes. For diabetes patients, medical cost growth at 30 months is 6 points lower overall but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months but 7 points lower with consistent use. This suggests the low persistence rates documented elsewhere may be the primary barrier to realizing GLP-1 value, not the drug efficacy itself.
 
 ---
 

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
 
 The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
+
+Aon's finding that benefits scale dramatically with adherence (80%+ adherent cohort shows strongest effects across all outcomes) provides the mechanism for why affordability-driven discontinuation is so costly: the patients who stop due to cost are precisely those who would benefit most from continued use, and the savings only materialize after 12-18 months of consistent use.
+
 ---
 
 Relevant Notes:

domains/health/pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md

@@ -34,10 +34,16 @@ Some evidence indicates lower mortality rates among PACE enrollees, suggesting q
 
 
 ### Additional Evidence (extend)
-*Source: [[2021-02-00-pmc-japan-ltci-past-present-future]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2021-02-00-pmc-japan-ltci-past-present-future | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Japan's LTCI provides a national-scale comparison point for PACE's integrated care model. LTCI offers both facility-based and home-based care chosen by beneficiaries, integrating medical care with welfare services across 7 care level tiers. As of 2015, the system served 5+ million beneficiaries (17% of 65+ population) — compared to PACE's 90,000 enrollees in the US. If the US had equivalent coverage, that would represent ~11.4 million people. Japan's experience demonstrates that integrated care delivery can operate at national scale through mandatory insurance, though financial sustainability under extreme aging demographics (28.4% elderly, rising to 40%) remains an ongoing challenge requiring premium and copayment adjustments.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-16*
+
+2025 data shows PACE serves 80,815 enrollees across 198 programs in 33 states, with most fully integrated capitated model taking 100% responsibility for nursing-home-eligible patients. The report confirms PACE's value proposition is community-based care delivery for complex patients, not cost reduction. However, it adds critical context: nearly half of enrollees are served by just 10 parent organizations, and over half are concentrated in 3 states (CA, NY, PA), indicating the model works but faces severe scaling constraints that prevent national replication.
+
 ---
 
 Relevant Notes:
@@ -46,4 +52,4 @@ Relevant Notes:
 - [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem]]
 
 Topics:
-- [[health/_map]]
+- health/_map

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,12 +28,6 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
-
-### Additional Evidence (confirm)
-*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
-
-Aon's real-world data confirms downstream cost savings materialize after 12-18 months, with diabetes patients showing 6-9 percentage point lower medical cost growth at 30 months. This validates the kidney protection economic model—savings are real but require long-term risk-bearing to capture.
-
 ---
 
 Relevant Notes:

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -298,10 +298,10 @@ The Commonwealth Fund's 2024 international comparison provides evidence that the
 C-SNP growth of 71% in one year shows MA plans are rapidly building chronic disease management infrastructure. With 21% of MA enrollment now in SNPs (up from 14% in 2020), the market is structurally shifting toward continuous care management models that align with prevention-first economics.
 
 
-### Additional Evidence (confirm)
-*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
+### Additional Evidence (challenge)
+*Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-16*
 
-GLP-1 economics demonstrate the payment alignment requirement: identical drug, identical clinical outcomes, but opposite financial incentives for short-term (employer) vs long-term (MA) risk-bearers. The 12-18 month lag between costs and savings means only aligned payment structures can profit from prevention.
+PACE is the strongest counter-evidence to attractor state inevitability. Operating since the 1970s with full capitation for the most complex Medicare/Medicaid patients (avg 76 years, 7+ chronic conditions, nursing-home eligible), PACE has achieved only 0.13% Medicare penetration (80,815 enrollees out of 67M eligible) as of 2025. Seven structural barriers prevent scaling despite clinical success: capital requirements, awareness deficits, insufficient enrollee concentration, geographic concentration in 3 states, dual-eligibility requirements, state-by-state regulatory complexity, and single-state operator structures. The 50-year timeline proves that model superiority does not guarantee market adoption—structural barriers can indefinitely prevent the attractor state even when the model demonstrably works.
 
 ---
 

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -19,22 +19,28 @@ The Making Care Primary model's termination in June 2025 (after just 12 months,
 
 
 ### Additional Evidence (extend)
-*Source: [[2014-00-00-aspe-pace-effect-costs-nursing-home-mortality]] | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2014-00-00-aspe-pace-effect-costs-nursing-home-mortality | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5*
 
 PACE represents the extreme end of value-based care alignment—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment, PACE does not reduce total costs but redistributes them (lower Medicare acute costs in early months, higher Medicaid chronic costs overall). This suggests that the 'payment boundary' stall may not be primarily a problem of insufficient risk-bearing. Rather, the economic case for value-based care may rest on quality/preference improvements rather than cost reduction. PACE's 'stall' is not at the payment boundary—it's at the cost-savings promise. The implication: value-based care may require a different success metric (outcome quality, institutionalization avoidance, mortality reduction) than the current cost-reduction narrative assumes.
 
 
 ### Additional Evidence (extend)
-*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15*
 
 Medicare Advantage plans bearing full capitated risk increased GLP-1 prior authorization from <5% to nearly 100% within two years (2023-2025), demonstrating that even full-risk capitation does not automatically align incentives toward prevention when short-term cost pressures dominate. Both BCBS and UnitedHealthcare implemented universal PA despite theoretical alignment under capitation.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-16*
+
+PACE represents the 100% risk endpoint—full capitation for all medical, social, and psychiatric needs, entirely replacing Medicare and Medicaid cards. Yet even at full risk with proven outcomes for the highest-cost patients, PACE serves only 0.13% of Medicare eligibles after 50 years. This suggests the stall point is not just at the payment boundary (partial vs full risk) but at the scaling boundary—capital, awareness, regulatory, and operational barriers prevent even successful full-risk models from achieving market penetration. The gap between 14% bearing full risk and PACE's 0.13% penetration indicates that moving from partial to full risk is necessary but insufficient for VBC transformation.
+
 ---
 
 Relevant Notes:

domains/internet-finance/backpressure-prevents-pipeline-failure-by-creating-feedback-loop-between-consumer-capacity-and-producer-rate.md

@@ -32,6 +32,12 @@ The Teleo pipeline currently has zero backpressure. The extract-cron.sh dispatch
 
 Simple implementation: extraction dispatcher should check open PR count before dispatching. If open PRs exceed threshold, reduce extraction parallelism or skip the cycle entirely. This creates the feedback loop that prevents eval queue overload.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-00-javacodegeeks-reactive-programming-backpressure-stream-processing]] | Added: 2026-03-16*
+
+Reactive Streams specification implements backpressure through Publisher/Subscriber/Subscription interfaces where Subscriber requests N items and Publisher delivers at most N, creating demand-based flow control. Four standard strategies exist: Buffer (accumulate with threshold triggers, risk unbounded memory), Drop (discard excess), Latest (keep only most recent), and Error (signal failure on overflow). Key architectural insight: backpressure must be designed into systems from the start—retrofitting it is much harder.
+
 ---
 
 Relevant Notes:

domains/internet-finance/futarchy-excels-at-relative-selection-but-fails-at-absolute-prediction-because-ordinal-ranking-works-while-cardinal-estimation-requires-calibration.md

@@ -35,13 +35,19 @@ This was a play-money experiment, which is the primary confound. Real-money futa
 
 ORE's HNT-ORE boost proposal demonstrates futarchy's strength in relative selection: the market validated HNT as the next liquidity pair to boost relative to other candidates (ISC already had a boost at equivalent multiplier), but the proposal does not require absolute prediction of HNT's future price or utility—only that HNT is a better strategic choice than alternatives. The proposal passed by market consensus on relative positioning (HNT as flagship DePIN project post-HIP-138), not by predicting absolute HNT performance metrics.
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-11-25-futardio-proposal-launch-a-boost-for-hnt-ore]] | Added: 2026-03-16*
+
+ORE's three-tier boost multiplier system (vanilla stake, critical pairs, extended pairs) demonstrates futarchy's strength at relative ranking. The proposal doesn't require markets to predict absolute HNT-ORE liquidity outcomes, only to rank this boost against alternatives. Future proposals apply to tiers as wholes, further simplifying the ordinal comparison task.
+
 ---
 
 Relevant Notes:
-- [[MetaDAOs futarchy implementation shows limited trading volume in uncontested decisions.md]]
-- [[speculative markets aggregate information through incentive and selection effects not wisdom of crowds.md]]
-- [[optimal governance requires mixing mechanisms because different decisions have different manipulation risk profiles.md]]
+- MetaDAOs futarchy implementation shows limited trading volume in uncontested decisions.md
+- speculative markets aggregate information through incentive and selection effects not wisdom of crowds.md
+- optimal governance requires mixing mechanisms because different decisions have different manipulation risk profiles.md
 
 Topics:
-- [[domains/internet-finance/_map]]
-- [[foundations/collective-intelligence/_map]]
+- domains/internet-finance/_map
+- foundations/collective-intelligence/_map

domains/internet-finance/futarchy-incentive-programs-use-multisig-execution-groups-as-discretionary-override.md

@@ -11,6 +11,12 @@ created: 2026-03-15
 
 The Drift proposal establishes a 2/3 multisig execution group (metaprophet, Sumatt, Lmvdzande) to distribute the 50,000 DRIFT budget according to the outlined rules. Critically, the proposal grants this group discretion in two areas: (1) determining 'exact criteria' for the activity pool to filter non-organic participation, and (2) deciding which proposals qualify if successful proposals exceed the budget. The group also receives 3,000 DRIFT for their work and has authority to return excess funds to the treasury. This structure acknowledges that pure algorithmic distribution fails when faced with gaming, ambiguous cases, or unforeseen circumstances. The multisig provides a credible commitment mechanism - the proposal passes based on general principles, but execution requires human judgment. The group composition (known futarchy advocates) provides reputational accountability.
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-12-19-futardio-proposal-allocate-50000-drift-to-fund-the-drift-ai-agent-request-for]] | Added: 2026-03-16*
+
+The Drift proposal explicitly states 'All grant decisions are at the discretion of the decision council and any such decisions made by the decision council are final.' This creates a hybrid structure where futarchy approves the program budget but a committee controls individual allocations, demonstrating the pattern of discretionary override for operational decisions.
+
 ---
 
 Relevant Notes:

domains/internet-finance/futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs.md

@@ -28,10 +28,16 @@ The single data point is limited. One passed proposal doesn't establish a reliab
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure]] | Added: 2026-03-15*
+*Source: 2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure | Added: 2026-03-15*
 
 Dean's List DAO's fee increase proposal included switching quote token from mSOL back to SOL, a decision with no direct revenue impact but potential effects on user experience and composability. The futarchy market approved this alongside the fee changes, suggesting it priced the operational simplification and ecosystem alignment as net positive for token value despite being a 'cultural' rather than purely financial decision.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-11-25-futardio-proposal-launch-a-boost-for-hnt-ore]] | Added: 2026-03-16*
+
+The HNT-ORE boost proposal frames strategic partnership value through liquidity network effects and brand positioning ('flagship DePIN project', 'competitive unit of account for real world assets'). Markets must price whether Helium association increases ORE's perceived legitimacy and network depth, demonstrating futarchy's ability to evaluate partnership proposals with significant intangible components.
+
 ---
 
 Relevant Notes:

domains/internet-finance/futarchy-proposals-with-favorable-economics-can-fail-due-to-participation-friction-not-market-disagreement.md

@@ -45,13 +45,13 @@ However, this case provides concrete evidence that [[futarchy adoption faces fri
 
 
 ### Additional Evidence (confirm)
-*Source: [[2024-08-27-futardio-proposal-fund-the-drift-superteam-earn-creator-competition]] | Added: 2026-03-15*
+*Source: 2024-08-27-futardio-proposal-fund-the-drift-superteam-earn-creator-competition | Added: 2026-03-15*
 
 Drift's $8,250 creator competition proposal failed despite having clear upside potential (community engagement, content generation, B.E.T awareness) and minimal downside risk. The proposal offered a structured prize pool across multiple tracks (video, Twitter threads, trade ideas) with established evaluation criteria, yet still failed to generate sufficient market participation. This is a canonical example of participation friction killing an economically sensible proposal.
 
 
 ### Additional Evidence (extend)
-*Source: [[2024-12-02-futardio-proposal-approve-deans-list-treasury-management]] | Added: 2026-03-15*
+*Source: 2024-12-02-futardio-proposal-approve-deans-list-treasury-management | Added: 2026-03-15*
 
 Dean's List treasury proposal passed despite requiring active market participation to price a 40 percentage point survival probability improvement. The proposal explicitly calculated that potential FDV increase (5-20%) exceeded the 3% TWAP threshold, suggesting the economics were clearly favorable yet still required formal market validation.
 
@@ -61,6 +61,12 @@ Dean's List treasury proposal passed despite requiring active market participati
 
 Dean's List DAO fee structure proposal passed despite requiring traders to actively migrate to new pools and accept 20x higher fees (0.25% to 5%). The proposal explicitly acknowledged potential 20-30% volume decrease but passed anyway, suggesting the market priced the net treasury benefit (~$19k-25k annual growth) as worth the migration friction. This demonstrates that futarchy can approve proposals with significant user friction when the economic benefit is clear.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure]] | Added: 2026-03-16*
+
+Dean's List DAO proposal passed with TWAP threshold requiring only 3% MCAP increase ($307,855 vs $298,889 baseline), suggesting the market viewed the fee increase as marginally positive but not strongly so. The conservative 3% threshold indicates either low participation or weak conviction despite clear revenue projections showing 20x fee increase.
+
 ---
 
 Relevant Notes:

domains/internet-finance/high-fee-amms-create-lp-incentive-and-manipulation-deterrent-simultaneously-by-making-passive-provision-profitable-and-active-trading-expensive.md

@@ -38,10 +38,16 @@ The mechanism depends on futarchy-specific conditions (short duration, governanc
 
 
 ### Additional Evidence (confirm)
-*Source: [[2024-01-24-futardio-proposal-develop-amm-program-for-futarchy]] | Added: 2026-03-16*
+*Source: 2024-01-24-futardio-proposal-develop-amm-program-for-futarchy | Added: 2026-03-16*
 
 MetaDAO's AMM proposal sets fees at 3-5% explicitly to 'both: encourage LPs, and aggressively discourage wash-trading and manipulation.' The mechanism works because high fees make price manipulation through wash trading expensive while creating strong incentives for liquidity provision.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure]] | Added: 2026-03-16*
+
+Dean's List DAO increased swap fees from 0.25% to 5% base (up to 10%) specifically to create a tiered market structure where large trades accept higher fees for deep liquidity while small trades use individual LP pools with lower fees. The proposal explicitly states this creates 'earning opportunities for DAO contributors' through the fee differential, with projected annual treasury growth of $19,416-$24,960 despite expected 20-30% volume decrease.
+
 ---
 
 Relevant Notes:

domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md

@@ -32,16 +32,22 @@ The source presents no failure cases despite eight ICOs, which suggests either s
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-10-14-futardio-launch-avici]] | Added: 2026-03-15*
+*Source: 2025-10-14-futardio-launch-avici | Added: 2026-03-15*
 
 Avici achieved 17x oversubscription ($34.2M committed vs $2M target), exceeding the previously documented 15x benchmark and demonstrating continued strong market demand for futarchy-governed raises.
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-10-18-futardio-launch-loyal]] | Added: 2026-03-15*
+*Source: 2025-10-18-futardio-launch-loyal | Added: 2026-03-15*
 
 Loyal's fundraise achieved 151x oversubscription ($75.9M committed vs $500K target), far exceeding the previously documented 15x pattern. The final raise settled at $2.5M, suggesting the platform's conditional market mechanisms successfully filtered commitment from actual capital deployment.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-11-14-futardio-launch-solomon]] | Added: 2026-03-16*
+
+Solomon raised $102.9M committed against $2M target (51x oversubscription), closing at $8M final raise. This adds to the pattern of massive oversubscription on futarchy-governed launches, following earlier examples like Cult's $11.4M single-day raise.
+
 ---
 
 Relevant Notes:

domains/internet-finance/pro-rata-ico-allocation-creates-capital-inefficiency-through-massive-oversubscription-refunds.md

@@ -28,6 +28,12 @@ The convergence toward lower volatility in recent launches (maximum 30% drawdown
 ## Limitations
 The lower volatility in recent launches could reflect declining speculative interest rather than superior price discovery. The capital efficiency problem may be solvable through secondary markets for subscription rights or through hybrid mechanisms that combine pro-rata allocation with price discovery. This analysis is based on a single source and limited to 8 data points, warranting experimental confidence.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-11-14-futardio-launch-solomon]] | Added: 2026-03-16*
+
+Solomon's 51x oversubscription ($102.9M committed vs $8M accepted) required returning $94.9M to participants, demonstrating the capital inefficiency of oversubscribed raises even when the platform caps final acceptance.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-01-01-sage-algorithmic-content-creation-systematic-review.json

@@ -0,0 +1,27 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 4,
+    "rejected": 1,
+    "fixes_applied": [
+      "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md:set_created:2026-03-16",
+      "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md:stripped_wiki_link:content-serving-commercial-functions-can-simultaneously-serv",
+      "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md:stripped_wiki_link:creator-owned-direct-subscription-platforms-produce-qualitat",
+      "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md:stripped_wiki_link:established-creators-generate-more-revenue-from-owned-stream"
+    ],
+    "rejections": [
+      "algorithmic-content-optimization-pressure-is-mediated-by-revenue-model-not-algorithm-design.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/.extraction-debug/2025-03-17-norc-pace-market-assessment-for-profit-expansion.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-attractor-state-despite-model-success.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "for-profit-pace-entry-signals-potential-scaling-inflection-through-capital-and-operational-capacity.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-attractor-state-despite-model-success.md:set_created:2026-03-16",
+      "for-profit-pace-entry-signals-potential-scaling-inflection-through-capital-and-operational-capacity.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-attractor-state-despite-model-success.md:missing_attribution_extractor",
+      "for-profit-pace-entry-signals-potential-scaling-inflection-through-capital-and-operational-capacity.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/.extraction-debug/2026-01-01-koinsights-authenticity-premium-ai-rejection.json

@@ -0,0 +1,27 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md",
+      "issues": [
+        "no_frontmatter"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 4,
+    "rejected": 1,
+    "fixes_applied": [
+      "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md:set_created:2026-03-16",
+      "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md:stripped_wiki_link:consumer-acceptance-of-ai-creative-content-declining-despite",
+      "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md:stripped_wiki_link:consumer-ai-acceptance-diverges-by-use-case-with-creative-wo",
+      "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md:stripped_wiki_link:GenAI adoption in entertainment will be gated by consumer ac"
+    ],
+    "rejections": [
+      "ai-authorship-creates-moral-disgust-response-in-emotionally-meaningful-contexts-regardless-of-content-quality.md:no_frontmatter"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/.extraction-debug/2026-01-01-mckinsey-ai-film-tv-production-future.json

@@ -0,0 +1,40 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "historical-entertainment-technology-transitions-produce-35-percent-revenue-contraction-for-incumbents-within-five-years.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "ai-production-efficiency-gains-accrue-primarily-to-distributors-not-producers-because-of-structural-market-dynamics.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "fix-it-in-pre-workflow-shift-reallocates-value-from-post-production-to-pre-production-and-distributors.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 3,
+    "kept": 0,
+    "fixed": 3,
+    "rejected": 3,
+    "fixes_applied": [
+      "historical-entertainment-technology-transitions-produce-35-percent-revenue-contraction-for-incumbents-within-five-years.md:set_created:2026-03-16",
+      "ai-production-efficiency-gains-accrue-primarily-to-distributors-not-producers-because-of-structural-market-dynamics.md:set_created:2026-03-16",
+      "fix-it-in-pre-workflow-shift-reallocates-value-from-post-production-to-pre-production-and-distributors.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "historical-entertainment-technology-transitions-produce-35-percent-revenue-contraction-for-incumbents-within-five-years.md:missing_attribution_extractor",
+      "ai-production-efficiency-gains-accrue-primarily-to-distributors-not-producers-because-of-structural-market-dynamics.md:missing_attribution_extractor",
+      "fix-it-in-pre-workflow-shift-reallocates-value-from-post-production-to-pre-production-and-distributors.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json

@@ -1,13 +1,13 @@
 {
   "rejected_claims": [
     {
-      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
+      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
       "issues": [
         "missing_attribution_extractor"
       ]
     },
     {
-      "filename": "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md",
+      "filename": "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -19,12 +19,12 @@
     "fixed": 2,
     "rejected": 2,
     "fixes_applied": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
-      "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:set_created:2026-03-16"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
+      "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md:set_created:2026-03-16"
     ],
     "rejections": [
-      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
-      "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:missing_attribution_extractor"
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
+      "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-suggesting-multi-organ-protective-mechanisms-beyond-metabolic-effects.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",

inbox/archive/2024-00-00-alea-research-metadao-fair-launches.md

@@ -4,7 +4,7 @@ title: "Alea Research: MetaDAO's Fair Launch Model Analysis"
 url: https://alearesearch.substack.com/p/metadaos-fair-launches
 archived_date: 2024-00-00
 format: article
-status: processing
+status: unprocessed
 processed_date: 2024-03-11
 extraction_model: claude-3-7-sonnet-20250219
 enrichments:

inbox/archive/2024-11-25-futardio-proposal-launch-a-boost-for-hnt-ore.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/proposal/2QUxbiMkDtoKxY2u6kXuevfMsqKGtHNxMFYHVWbqRK1
 date: 2024-11-25
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
 processed_by: rio
@@ -14,6 +14,10 @@ processed_date: 2026-03-11
 enrichments_applied: ["futarchy-excels-at-relative-selection-but-fails-at-absolute-prediction-because-ordinal-ranking-works-while-cardinal-estimation-requires-calibration.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "Futardio proposal for ORE-HNT liquidity boost. Primary extraction: three new entities (ORE protocol, decision_market for the proposal, Helium). Two enrichments showing futarchy governance patterns: three-tier boost system as governance simplification mechanism, and strategic partnership evaluation through conditional markets. No novel claims — the proposal demonstrates existing futarchy mechanisms in practice rather than introducing new theoretical insights."
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["futarchy-excels-at-relative-selection-but-fails-at-absolute-prediction-because-ordinal-ranking-works-while-cardinal-estimation-requires-calibration.md", "futarchy-markets-can-price-cultural-spending-proposals-by-treating-community-cohesion-and-brand-equity-as-token-price-inputs.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -71,3 +75,12 @@ With the passing of this proposal, we would introduce a new boost with the same
 - HNT-ORE boost uses Kamino kTokens representing concentrated liquidity positions on Orca
 - ORE three-tier boost system: Tier 1 (vanilla stake), Tier 2 (SOL-ORE, USDC-ORE), Tier 3 (ISC-ORE, HNT-ORE)
 - Helium HIP-138 consolidated network tokenomics around HNT as primary token
+
+
+## Key Facts
+- ORE proposal 2QUxbiMkDtoKxY2u6kXuevfMsqKGtHNxMFYHVWbqRK1A passed 2024-11-28
+- HNT-ORE boost uses Kamino kTokens representing concentrated liquidity positions on Orca
+- ORE three-tier boost system: Tier 1 (vanilla stake), Tier 2 (SOL-ORE, USDC-ORE), Tier 3 (ISC-ORE, HNT-ORE)
+- Helium HIP-138 consolidated network tokenomics around HNT as primary token
+- ORE's strategic goal is building deep liquidity network for all real world assets on Solana
+- ORE focuses exclusively on tokenized commodities and DePIN credits

inbox/archive/2024-12-19-futardio-proposal-allocate-50000-drift-to-fund-the-drift-ai-agent-request-for.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/proposal/A74H61YqwsbwRczuErbUyh9kqG1A7ZbiE1W5hWZmT9f
 date: 2024-12-19
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["futarchy-incentive-programs-use-multisig-execution-groups-as-discretionary-override.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -133,3 +137,13 @@ This comes at a cost of 50k DRIFT tokens to the foundation.
 - Autocrat version: 0.3
 - Completed: 2024-12-22
 - Ended: 2024-12-22
+
+
+## Key Facts
+- Drift AI Agents RFG allocated 50,000 DRIFT total for grants
+- Individual grant amounts range from 10,000-20,000 DRIFT
+- Application deadline set for March 1st, 2025
+- Unused grants returned to foundation after deadline
+- Proposal passed on December 22, 2024
+- Grant deployment requires KYC for regulatory compliance
+- Target areas include trading agents, yield agents, information agents, and social agents

inbox/archive/2025-01-01-sage-algorithmic-content-creation-systematic-review.md

@@ -7,10 +7,14 @@ date: 2025-01-01
 domain: entertainment
 secondary_domains: [ai-alignment]
 format: academic-article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [algorithmic-pressure, content-creation, creative-freedom, platform-dependency, storytelling-quality]
 flagged_for_theseus: ["Algorithmic shaping of creative expression — parallels with AI alignment concerns about optimization pressure distorting human values"]
+processed_by: clay
+processed_date: 2026-03-16
+enrichments_applied: ["content-serving-commercial-functions-can-simultaneously-serve-meaning-functions-when-revenue-model-rewards-relationship-depth.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -42,3 +46,11 @@ Counterpoint evidence:
 PRIMARY CONNECTION: [[meme propagation selects for simplicity novelty and conformity pressure rather than truth or utility]]
 WHY ARCHIVED: Academic evidence that algorithmic pressure degrades creative expression, BUT the pressure is mediated by revenue model — creators who escape ad-supported dependency escape the pressure
 EXTRACTION HINT: The key variable is REVENUE MODEL, not ALGORITHM. Algorithms are the mechanism, but the revenue model determines whether the algorithm controls creative decisions. Content-as-loss-leader, subscription, and owned-platform models all insulate creators from algorithmic creative pressure.
+
+
+## Key Facts
+- Systematic review published in Work, Employment and Society (SAGE Journals), January 2025
+- Authors: Yin Liang, Jiaming Li, Jeremy Aroles, Edward Granter
+- Review covers full academic literature on algorithmic impacts on creative work
+- LinkedIn algorithm now emphasizes authentic professional storytelling over promotional content
+- LinkedIn algorithm actively demotes content with excessive hashtags, external links in post text, and engagement baiting

inbox/archive/2025-01-14-futardio-proposal-should-deans-list-dao-update-the-liquidity-fee-structure.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/proposal/B8WLuXqoBb3hRD9XBCNuSqxDqCXCixqRdKR4pVFGzNP
 date: 2025-01-14
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["high-fee-amms-create-lp-incentive-and-manipulation-deterrent-simultaneously-by-making-passive-provision-profitable-and-active-trading-expensive.md", "futarchy-proposals-with-favorable-economics-can-fail-due-to-participation-friction-not-market-disagreement.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -165,3 +169,13 @@ Current MCAP will be -5% of the MCAP at the time of the proposal to account for
 - Autocrat version: 0.3
 - Completed: 2025-01-17
 - Ended: 2025-01-17
+
+
+## Key Facts
+- Dean's List DAO had ~$80,000 treasury and $298,889 MCAP as of January 11, 2025
+- Dean's List DAO monthly trading volume was 46,228 USDC (Dec 6 - Jan 6)
+- Current 0.25% fee generated ~3.85 USDC daily revenue
+- Proposed 5% fee would generate ~77 USDC daily at current volume
+- Proposal used -5% MCAP buffer to account for volatility: $314,620 - $15,731 = $298,889
+- Pass threshold set at current MCAP + 3% = $307,855
+- Proposal also changed quote token from mSOL back to SOL

inbox/archive/2025-03-17-norc-pace-market-assessment-for-profit-expansion.md

@@ -7,9 +7,13 @@ date: 2025-03-17
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [pace, all-inclusive-care, elderly, capitated-care, scaling-barriers, for-profit, integrated-care]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -69,3 +73,12 @@ tags: [pace, all-inclusive-care, elderly, capitated-care, scaling-barriers, for-
 PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 WHY ARCHIVED: PACE is the strongest counter-evidence and supporting evidence simultaneously — it proves the model works AND that structural barriers prevent scaling. Essential for honest distance measurement.
 EXTRACTION HINT: The 0.13% penetration after 50 years is the key number. Compare to MA's 54% — what does the gap reveal about what actually scales in US healthcare?
+
+
+## Key Facts
+- PACE serves individuals 55+ needing nursing home-level care through government funding
+- PACE average member: 76 years old, 7+ chronic conditions, nursing-home eligible
+- Nearly half of PACE enrollees served by 10 largest parent organizations
+- Only 13 states have 1,000+ PACE enrollees
+- Most PACE parent organizations operate single program in one state
+- PACE eligibility contingent on Medicare + Medicaid dual status

inbox/archive/2025-10-06-futardio-launch-umbra.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9kx7UDFzFt7e2V4pFtawnupKKvRR3EhV7P1Pxmc5XCQj"
 date: 2025-10-06
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2025-11-14-futardio-launch-solomon.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/634r63NH2qbTrSVyLieC3Ab3YKaEfoGnCLM8idZMEycE"
 date: 2025-11-14
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md", "pro-rata-ico-allocation-creates-capital-inefficiency-through-massive-oversubscription-refunds.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Launch Details
@@ -69,3 +73,14 @@ Solomon is the first stablecoin system that can sit everywhere money sits. Walle
 - Version: v0.6
 - Final raise: $8,000,000.00
 - Closed: 2025-11-18
+
+
+## Key Facts
+- Solomon raised $102,932,673.08 committed against $2M target on futard.io
+- Solomon closed at $8M final raise on 2025-11-18
+- Solomon's raise structure: 20% of gross to MetaDAO for token liquidity, 80% nets to Solomon DAO treasury
+- Solomon ran closed beta for one year with seven-figure TVL before public launch
+- Solomon custody is segregated with Ceffu and carries insurance coverage
+- Solomon Solana programs are audited with admin operations via Squads multisig
+- Solomon survived October 10, 2024 Binance price dislocation with zero incidents
+- Solomon's basis trade strategy targets ~16% APR on treasury capital

inbox/archive/2025-12-00-javacodegeeks-reactive-programming-backpressure-stream-processing.md

@@ -6,8 +6,12 @@ url: https://www.javacodegeeks.com/2025/12/reactive-programming-paradigms-master
 date: 2025-12-01
 domain: internet-finance
 format: essay
-status: unprocessed
+status: enrichment
 tags: [pipeline-architecture, backpressure, reactive-streams, flow-control, producer-consumer]
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["backpressure-prevents-pipeline-failure-by-creating-feedback-loop-between-consumer-capacity-and-producer-rate.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 # Reactive Programming Paradigms: Mastering Backpressure and Stream Processing
@@ -29,3 +33,9 @@ Practitioner guide to implementing backpressure in reactive stream processing sy
 ## Relevance to Teleo Pipeline
 
 Our pipeline currently has NO backpressure. Extract produces PRs that accumulate in eval's queue without any feedback mechanism. If research dumps 20 sources, extraction creates 20 PRs, and eval drowns trying to process them all. We need a "buffer + rate limit" strategy: extraction should check eval queue depth before starting new work, and slow down or pause when eval is backlogged.
+
+
+## Key Facts
+- Reactive Streams standard defines Publisher/Subscriber/Subscription interfaces for demand-based flow control
+- Four backpressure strategies: Buffer, Drop, Latest, Error
+- Practical implementations include Project Reactor (Spring WebFlux), Akka Streams, RxJava

inbox/archive/2025-12-23-jama-cardiology-select-hospitalization-analysis.md

@@ -7,9 +7,13 @@ date: 2025-12-23
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, hospitalization, cardiovascular, SELECT-trial, cost-offset]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -36,3 +40,12 @@ Median age 61.0 years; 27.7% female; median BMI 32.1.
 PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 WHY ARCHIVED: All-cause hospitalization reduction is the most economically relevant outcome for risk-bearing payers and the strongest evidence that GLP-1s could be cost-saving under capitation
 EXTRACTION HINT: Focus on the all-cause hospitalization signal (not just CV) — this is what makes GLP-1s relevant to VBC economics beyond cardiology
+
+
+## Key Facts
+- SELECT trial: N=17,604 patients with obesity and established CVD, median follow-up 41.8 months
+- Median age 61.0 years, 27.7% female, median BMI 32.1
+- Total hospitalizations: 18.3 vs 20.4 per 100 patient-years (mean ratio 0.90, P<.001)
+- Hospitalizations for serious adverse events: 15.2 vs 17.1 per 100 patient-years (mean ratio 0.89, P<.001)
+- Days hospitalized: 157.2 vs 176.2 per 100 patient-years (rate ratio 0.89, P=.01)
+- Published in JAMA Cardiology as prespecified exploratory analysis

inbox/archive/2026-01-01-futardio-launch-p2p.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ"
 date: 2026-01-01
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "LLM returned 0 claims, 0 rejected by validator"
 ---
 
 ## Launch Details
@@ -25,3 +29,10 @@ event_type: launch
 - Token: P2P (P2P)
 - Token mint: `P2PXup1ZvMpCDkJn3PQxtBYgxeCSfH39SFeurGSmeta`
 - Version: v0.7
+
+
+## Key Facts
+- P2P launched on Futard.io on 2026-01-01 with $6M funding target
+- P2P uses Autocrat v0.7 for futarchy governance
+- P2P token mint address is P2PXup1ZvMpCDkJn3PQxtBYgxeCSfH39SFeurGSmeta
+- Launch address is H5ng9t1tPRvGx8QoLFjjuXKdkUjicNXiADFdqB6t8ifJ

inbox/archive/2026-01-01-futardio-launch-quantum-waffle.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/4Wm4NFVy9MKgSJe3ZT8aKwbL3dc5XxvnWdPhvC4Sinow"
 date: 2026-01-01
 domain: internet-finance
 format: data
-status: unprocessed
+status: null-result
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "LLM returned 0 claims, 0 rejected by validator"
 ---
 
 ## Launch Details
@@ -54,3 +58,11 @@ Replace every quantum crypto whitepaper with a picture of a waffle
 - Token: Ase (Ase)
 - Token mint: `Asea2u9y3iwm8nNJ9uRtyeHoLYUHNWR48NJNKGCpmeta`
 - Version: v0.7
+
+
+## Key Facts
+- Quantum Waffle launched on Futardio 2026-01-01 seeking $50,000
+- Launch address: 4Wm4NFVy9MKgSJe3ZT8aKwbL3dc5XxvnWdPhvC4Sinow
+- Token mint: Asea2u9y3iwm8nNJ9uRtyeHoLYUHNWR48NJNKGCpmeta
+- Project describes itself as flappy bird clone with quantum branding
+- Futardio platform version: v0.7

inbox/archive/2026-01-01-koinsights-authenticity-premium-ai-rejection.md

@@ -7,9 +7,13 @@ date: 2026-01-01
 domain: entertainment
 secondary_domains: [cultural-dynamics]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [authenticity-premium, consumer-rejection, AI-content, trust-penalty, epistemic-anxiety]
+processed_by: clay
+processed_date: 2026-03-16
+enrichments_applied: ["GenAI adoption in entertainment will be gated by consumer acceptance not technology capability.md", "consumer-acceptance-of-ai-creative-content-declining-despite-quality-improvements-because-authenticity-signal-becomes-more-valuable.md", "consumer-ai-acceptance-diverges-by-use-case-with-creative-work-facing-4x-higher-rejection-than-functional-applications.md", "human-made-is-becoming-a-premium-label-analogous-to-organic-as-AI-generated-content-becomes-dominant.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -40,3 +44,9 @@ O'Neill identifies contexts where authenticity premiums emerge most strongly: hi
 PRIMARY CONNECTION: [[GenAI adoption in entertainment will be gated by consumer acceptance not technology capability]]
 WHY ARCHIVED: Provides mechanism update for existing binding constraint claim — rejection is epistemic/moral, not aesthetic
 EXTRACTION HINT: Focus on the VALUES-BASED dimension of rejection and the "moral disgust" finding. This is a different mechanism than "consumers can't tell the difference."
+
+
+## Key Facts
+- Deloitte 2024 Connected Consumer Survey found nearly 70% of respondents are concerned AI-generated content will be used to deceive them
+- Approximately half of consumers believe they can recognize AI-written content
+- McDonald's Netherlands Christmas ad production involved 10 people working full-time for five weeks before being pulled due to backlash

inbox/archive/2026-01-01-mckinsey-ai-film-tv-production-future.md

@@ -7,9 +7,13 @@ date: 2026-01-01
 domain: entertainment
 secondary_domains: [teleological-economics]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [AI-production, value-redistribution, cost-collapse, disruption-economics, film-industry]
+processed_by: clay
+processed_date: 2026-03-16
+enrichments_applied: ["non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain.md", "media disruption follows two sequential phases as distribution moats fall first and creation moats fall second.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -52,3 +56,11 @@ Three major technology shifts each resulted in ~35% revenue contraction for incu
 PRIMARY CONNECTION: [[non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain]]
 WHY ARCHIVED: Authoritative financial projections ($60B redistribution, 35% contraction pattern) and the COUNTER-FINDING that distributors, not producers, capture most AI value
 EXTRACTION HINT: The distributor value capture finding is the most important — it complicates the "AI democratizes creation" narrative. Also: the 35% contraction pattern is a strong historical regularity worth claiming.
+
+
+## Key Facts
+- $60B annual revenue redistribution projected within five years of mass AI adoption in entertainment
+- $13.2B projected decline in US TV/film distribution revenues if open platforms capture additional 5% of viewing hours
+- $7.5B partial offset from increased open-platform revenues in same scenario
+- B5 Studios' Sean Bailey quoted: 'every single piece' of workflow from ideation to distribution will be significantly disrupted
+- McKinsey interviewed 20+ studio executives, producers, AI innovators, and academics for the report

inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -12,7 +12,7 @@ priority: high
 tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
 processed_by: vida
 processed_date: 2026-03-16
-enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"]
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
@@ -59,8 +59,8 @@ flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health inves
 - Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
 - First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
 - After 12 months: medical costs grow 2% vs 6% for non-users
-- Diabetes indication: 6 percentage points lower cost growth at 30 months; 9 points with 80%+ adherence
-- Weight loss indication: 3 points lower cost growth at 18 months; 7 points with consistent use
+- Diabetes indication at 30 months: medical cost growth 6 points lower, 9 points lower with 80%+ adherence
+- Weight loss indication at 18 months: cost growth 3 points lower, 7 points lower with consistent use
 - Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
-- MACE reduction: 47% for women, 26% for men among adherent users
-- Also associated with lower osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations
+- Adherent users (80%+): 47% MACE reduction for women, 26% for men
+- Study released January 13, 2026

inbox/archive/2026-02-21-futardio-launch-forevernow.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9FCpb4TmNkvrgkoiJzUm5vDBnQUqzSrUvxEvESBrns46"
 date: 2026-02-21
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-02-21-rakka-sol-omnipair-rate-controller.md

@@ -6,7 +6,7 @@ date: 2026-02-21
 archived_by: rio
 tags: [omnipair, rate-controller, interest-rates, capital-fragmentation]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---
 

inbox/archive/2026-02-25-futardio-launch-donuts.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/DYKhWPc3fQTsMEg6xpKttiZFMRzr8EjkQzFPxQyVRUyt"
 date: 2026-02-25
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-02-25-oxranga-solomon-lab-notes-05.md

@@ -6,7 +6,7 @@ date: 2026-02-25
 archived_by: rio
 tags: [solomon, YaaS, yield, audit, treasury, buyback, metadao-ecosystem]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---
 

inbox/archive/2026-02-28-futardio-launch-salmon-wallet.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/512ifHxPFoZa2GUHXi4mLUvJkFfBcZp4E7d1A7Y6EpGG"
 date: 2026-02-28
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-02-futardio-launch-reddit.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/HkF8CWrUYcnCjGmdhaQ2jyqfwMWioNK7PrJiAxhQx9i8"
 date: 2026-03-02
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-03-pineanalytics-metadao-q4-2025-quarterly-report.md

@@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2028683377251942707
 date: 2026-03-03
 tags: [rio, metadao, futarchy, quarterly-report, financial-data]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---
 

inbox/archive/2026-03-04-futardio-launch-lososdao.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Aji1A3Fu6iBSh6kAysG9TR5o4cPB1RxzYwWqw8Xkbc5o"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Gdyb1kNw26gve1VqU3zRxwZJhwJd5nAQ4goKNvAQBv9K"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-04-futardio-launch-pli-crperie-ambulante.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/GmNzSXzQ3q6UCVRpBf8PkvEqoo454Qr6twWc9zuzJzBa"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-04-futardio-launch-proph3t.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/316rXWmR84ppwS4FKfZQWPmwqQCQi4NRWCbeVwYqDPna"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-05-futardio-launch-ludex-ai.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/95HNkVuqzStFe7B6Aw32sgkbwkHEyEsA818izKKTz776"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio

inbox/archive/2026-03-05-pineanalytics-futardio-launch-metrics.md

@@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2029616320015159504
 date: 2026-03-05
 tags: [rio, metadao, futarchy, futardio, permissionless-launches]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---
 

inbox/archive/2026-03-09-rakka-omnipair-conversation.md

@@ -6,7 +6,7 @@ title: "OmniPair deep dive — mechanism design, competitive position, ecosystem
 date: 2026-03-09
 ingested: 2026-03-11
 ingested_by: rio
-status: processing
+status: unprocessed
 domain: internet-finance
 transcript_path: "~/.pentagon/voicenotes/transcripts/rakka.md"
 claims_extracted: []

skills/self-audit.md

@@ -0,0 +1,150 @@
+# Skill: Self-Audit
+
+Periodic self-examination of an agent's knowledge base for inconsistencies, weaknesses, and drift. Every agent runs this on their own domain.
+
+## When to Use
+
+- Every 50 claims added to your domain (condition-based trigger)
+- Monthly if claim volume is low
+- After a major belief update (cascade from upstream claim changes)
+- When preparing to publish positions (highest-stakes output deserves freshest audit)
+- On request from Leo or Cory
+
+## Principle: Detection, Not Remediation
+
+Self-audit is read-only. You detect problems and report them. You do NOT auto-fix.
+
+Fixes go through the standard PR process. This prevents the over-automation failure mode where silent corrections introduce new errors. The audit produces a report; the report drives PRs.
+
+## Process
+
+### Phase 1: Structural Scan (deterministic, automated)
+
+Run these checks on all claims in your domain (`domains/{your-domain}/`):
+
+**1. Schema compliance**
+- Every file has required frontmatter: `type`, `domain`, `description`, `confidence`, `source`, `created`
+- `confidence` is one of: `proven`, `likely`, `experimental`, `speculative`
+- `domain` matches the folder it lives in
+- Description adds information beyond the title (not a restatement)
+
+**2. Orphan detection**
+- Build incoming-link index: for each claim, which other claims link TO it via `title`
+- Claims with 0 incoming links and created > 7 days ago are orphans
+- Classify: "leaf contributor" (has outgoing links, no incoming) vs "truly isolated" (no links either direction)
+
+**3. Link health**
+- Every `wiki link` in the body should resolve to an actual file
+- Dangling links = either the target was renamed/deleted, or the link is aspirational
+- Report: list of broken links with the file they appear in
+
+**4. Staleness check**
+- Claims older than 180 days in fast-moving domains (health, ai-alignment, internet-finance)
+- Claims older than 365 days in slower domains (cultural-dynamics, critical-systems)
+- Cross-reference with git log: a claim file modified recently (enriched, updated) is not stale even if `created` is old
+
+**5. Duplicate detection**
+- Compare claim titles pairwise for semantic similarity
+- Flag pairs where titles assert nearly the same thing with different wording
+- This catches extraction drift — the same insight extracted from different sources as separate claims
+
+### Phase 2: Epistemic Self-Audit (LLM-assisted, requires judgment)
+
+Load your claims in batches (context window management — don't load all 50+ at once).
+
+**6. Contradiction scan**
+- Load claims in groups of 15-20
+- For each group, ask: "Do any of these claims contradict or tension with each other without acknowledging it?"
+- Tensions are fine if explicit (`challenged_by` field, or acknowledged in the body). UNACKNOWLEDGED tensions are the bug.
+- Cross-check: load claims that share wiki-link targets — these are most likely to have hidden tensions
+
+**7. Confidence calibration audit**
+- For each `proven` claim: does the body contain empirical evidence (RCTs, meta-analyses, large-N studies, mathematical proofs)? If not, it's overconfident.
+- For each `speculative` claim: does the body actually contain substantial evidence that might warrant upgrading to `experimental`?
+- For `likely` claims: is there counter-evidence elsewhere in the KB? If so, is it acknowledged?
+
+**8. Belief grounding check**
+- Read `agents/{your-name}/beliefs.md`
+- For each belief, verify the `depends_on` claims:
+  - Do they still exist? (not deleted or archived)
+  - Has their confidence changed since the belief was last evaluated?
+  - Have any been challenged with substantive counter-evidence?
+- Flag beliefs where supporting claims have shifted but the belief hasn't been re-evaluated
+
+**9. Gap identification**
+- Map your claims by subtopic. Where do you have single claims that should be clusters?
+- Check adjacent domains: what claims in other domains reference your domain but have no corresponding claim in your territory?
+- Check your beliefs: which beliefs have the thinnest evidence base (fewest supporting claims)?
+- Rank gaps by impact: gaps that affect active positions > gaps that affect beliefs > gaps in coverage
+
+**10. Cross-domain connection audit**
+- What percentage of your claims link to claims in other domains?
+- Healthy range: 15-30%. Below 15% = siloed. Above 30% = possibly under-grounded in own domain.
+- Which other domains SHOULD you connect to but don't? (Based on your beliefs and identity)
+
+### Phase 3: Report
+
+Produce a structured report. Format:
+
+```markdown
+# Self-Audit Report: {Agent Name}
+**Date:** YYYY-MM-DD
+**Domain:** {domain}
+**Claims audited:** N
+**Overall status:** healthy | warning | critical
+
+## Structural Findings
+- Schema violations: N (list)
+- Orphans: N (list with classification)
+- Broken links: N (list)
+- Stale claims: N (list with recommended action)
+- Potential duplicates: N (list pairs)
+
+## Epistemic Findings
+- Unacknowledged contradictions: N (list claim pairs with the tension)
+- Confidence miscalibrations: N (list with recommended adjustment)
+- Belief grounding issues: N (list beliefs with shifted dependencies)
+
+## Knowledge Gaps (ranked by impact)
+1. {Gap description} — affects belief/position X
+2. {Gap description} — affects belief/position Y
+
+## Cross-Domain Health
+- Linkage ratio: X%
+- Missing connections: {domains that should be linked but aren't}
+
+## Recommended Actions (prioritized)
+1. {Most impactful fix — usually an unacknowledged contradiction or belief grounding issue}
+2. {Second priority}
+3. ...
+```
+
+### Phase 4: Act on Findings
+
+- **Contradictions and miscalibrations** → create PRs to fix (highest priority)
+- **Orphans** → add incoming links from related claims (batch into one PR)
+- **Gaps** → publish as frontiers in `agents/{your-name}/frontier.md` (invites contribution)
+- **Stale claims** → research whether the landscape has changed, update or challenge
+- **Belief grounding issues** → trigger belief re-evaluation (may cascade to positions)
+
+## What Self-Audit Does NOT Do
+
+- Does not evaluate whether claims are TRUE (that's the evaluate skill + domain expertise)
+- Does not modify any files (detection only)
+- Does not audit other agents' domains (each agent audits their own)
+- Does not replace Leo's cross-domain evaluation (self-audit is inward-facing)
+
+## Relationship to Other Skills
+
+- **evaluate.md** — evaluates incoming claims. Self-audit evaluates existing claims.
+- **cascade.md** — propagates changes through the dependency chain. Self-audit identifies WHERE cascades are needed.
+- **learn-cycle.md** — processes new information. Self-audit reviews accumulated knowledge.
+- **synthesize.md** — creates cross-domain connections. Self-audit measures whether enough connections exist.
+
+## Frequency Guidelines
+
+| Domain velocity | Audit trigger | Expected duration |
+|----------------|--------------|-------------------|
+| Fast (health, AI, finance) | Every 50 claims or monthly | 1-2 hours |
+| Medium (entertainment, space) | Every 50 claims or quarterly | 1 hour |
+| Slow (cultural dynamics, critical systems) | Every 50 claims or biannually | 45 min |